Abstract
We report a case of 43-year-old male with advanced malignant mesothelioma (MM) with a large amount of fluid in the pleural and peritoneal cavity. The addition of endostar to the gemcitabine-cisplatin regimen gave a prompt and significant improvement of clinical symptoms and disappearance of ascites. The patient is still progression free after 27 months. Endostar, in combination with chemotherapy should be explored in the treatment of MM, especially its effect on pleural and ascitic fluid.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Ascites / etiology
-
Ascites / physiopathology
-
Ascites / prevention & control*
-
Ascitic Fluid / metabolism*
-
Cisplatin / administration & dosage
-
Cisplatin / therapeutic use
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Drug Resistance, Neoplasm
-
Endostatins / administration & dosage
-
Endostatins / therapeutic use*
-
Gemcitabine
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology
-
Lung Neoplasms / physiopathology
-
Male
-
Mesothelioma / drug therapy*
-
Mesothelioma / metabolism
-
Mesothelioma / pathology
-
Mesothelioma / physiopathology
-
Mesothelioma, Malignant
-
Neoplasm Staging
-
Pleural Effusion, Malignant / prevention & control*
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / therapeutic use
-
Secondary Prevention
-
Severity of Illness Index
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / metabolism*
Substances
-
Angiogenesis Inhibitors
-
Endostatins
-
Recombinant Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Deoxycytidine
-
endostar protein
-
Cisplatin
-
Gemcitabine